Dror Bashan bought $90k of PLX
PRESIDENT AND CEO at Protalix BioTherapeutics, Inc.. 64,516 shares at an average of $1.40, traded Oct 19, 2023, filed Oct 20, 2023.
Score components
- +25RoleCEO
- +9Trade size$90k at market
- +10Relative to holdingsHoldings up 95%
- +8Price context57% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.7%, 3m +0.7%, 6m -23.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-23-014454, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 19, 2023 | POpen-market purchase Common Stock | +48,387 | $1.40 | $68k | 116,387 | Oct 20, 2023 |
| Oct 19, 2023 | POpen-market purchase Common Stock | +16,129 | $1.41 | $23k | 132,516 | Oct 20, 2023 |
Related signals
Other insiders at Protalix BioTherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | PLXbuy Protalix BioTherapeutics, Inc. | Dror Bashan PRESIDENT AND CEO | $101k 56,000 shares | +42% | |
| 35Weak | PLXsell Protalix BioTherapeutics, Inc. | Amos Bar-Shalev director | $314 168 shares | -100% | |
| 37Weak | PLXbuy Protalix BioTherapeutics, Inc. | Aharon Schwartz director | $206k 129,000 shares | +74% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.